157 related articles for article (PubMed ID: 22954702)
1. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies.
Cheng M; Han J; Li Q; He B; Zha B; Wu J; Zhou R; Ye T; Wang W; Xu H; Hou Y
J Biomed Mater Res B Appl Biomater; 2012 Nov; 100(8):2035-43. PubMed ID: 22865703
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
7. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.
Cheng M; Xu H; Wang Y; Chen H; He B; Gao X; Li Y; Han J; Zhang Z
Drug Des Devel Ther; 2013; 7():1287-99. PubMed ID: 24187487
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Li S; Wang A; Jiang W; Guan Z
BMC Cancer; 2008 Apr; 8():103. PubMed ID: 18412945
[TBL] [Abstract][Full Text] [Related]
11. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
[TBL] [Abstract][Full Text] [Related]
12. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
13. In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles.
Yan C; Gu J; Guo Y; Chen D
Yakugaku Zasshi; 2010 Jun; 130(6):801-4. PubMed ID: 20519858
[TBL] [Abstract][Full Text] [Related]
14. [Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2].
Zhou JJ; Chen RF; Tang QB; Zhou QB; Lu HW; Wang J
Ai Zheng; 2006 Dec; 25(12):1459-63. PubMed ID: 17166367
[TBL] [Abstract][Full Text] [Related]
15. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice.
Zhang DY; Shen XZ; Wang JY; Dong L; Zheng YL; Wu LL
World J Gastroenterol; 2008 Jun; 14(22):3554-62. PubMed ID: 18567086
[TBL] [Abstract][Full Text] [Related]
16. Methylglyoxal in combination with 5-Fluorouracil elicits improved chemosensitivity in breast cancer through apoptosis and cell cycle inhibition.
Ghosh S; Pal A; Ray M
Biomed Pharmacother; 2019 Jun; 114():108855. PubMed ID: 31003140
[TBL] [Abstract][Full Text] [Related]
17. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Li Y; Han J; Zhang Z
Int J Nanomedicine; 2013; 8():4265-76. PubMed ID: 24232303
[TBL] [Abstract][Full Text] [Related]
19. Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.
Jin Y; Li J; Rong LF; Li YH; Guo L; Xu SY
World J Gastroenterol; 2005 May; 11(17):2643-6. PubMed ID: 15849826
[TBL] [Abstract][Full Text] [Related]
20. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.
Hou G; Yuan X; Li Y; Hou G; Liu X
Invest New Drugs; 2020 Apr; 38(2):329-339. PubMed ID: 31102118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
